Can a simple daily washout tame Post-Cancer bowel chaos?
NCT ID NCT07219745
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times
Summary
This pilot study tests whether a daily transanal irrigation (TAI) routine can help people who have bowel urgency, leakage, and diarrhea after rectal cancer surgery (low anterior resection syndrome). Sixty adults who have had a temporary ileostomy and are about to have it closed will either receive TAI training plus standard care or standard care alone. The main goal is to see if a larger trial is feasible, while also checking if TAI improves quality of life and bowel function in the first year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Peristeen Plus Irrigation kit (device for transanal irrigation)
- What this could lead to
- If successful, this could lead to a larger trial and potentially a simple daily routine to help people regain bowel control after rectal cancer surgery.
- What could go wrong
- This is a very small pilot study (60 people) to see if a bigger trial is even possible. It is not yet testing whether the treatment truly works, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults (≥18 years-old) patients who underwent a LAR for any indication via open, laparoscopic, robotic, or transanal total mesorectal excision, with creation of a diverting loop ileostomy, 2. have confirmed anastomotic healing demonstrated by flexible sigmoidoscopy and CT scan with rectally-administered water soluble contrast or gastrograffin enema, 3. are planned for an ileostomy closure operation, and 4. are in the first 12 months post-LAR operation Exclusion Criteria: 1. Inability to comprehend English or Spanish or provide informed consent (Note: after the English documents are approved, the study team plans to obtain a Spanish consent and study documents), 2. ongoing chemotherapy or radiotherapy, and 3. ongoing anastomotic complication.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Digestive Disease Institute Cleveland Clinic Florida
Weston, Florida, 33331, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?